Overview
As life sciences companies continue to grapple with increasingly complex and continuously evolving legal, business and regulatory issues, McDermott is pleased to bring our Life Sciences Legal Leadership Forum to Boston!
Join our cross-functional team of industry-focused life sciences lawyers for a half-day of CLE programming addressing the current state of the industry and the most pressing issues facing in-house counsel today – plus multiple networking opportunities with you in-house peers.
FEATURED SESSIONS INCLUDE:
IP Trends and Approaches for Life Sciences Companies: Discover the latest IP developments shaping Life Sciences companies. This panel will cover crucial topics, including navigating recent enablement decisions, updates on Europe’s Unified Patent Court, and practical insights on optimizing patent strategy and portfolio development in today’s dynamic environment.
Navigating the Licensing Landscape: Strategies and Insights: Join McDermott attorneys Rich Smith and Margaret Sampson for a real-time exploration of licensing. This session dives into the intricacies of negotiating license agreements, whether with academic institutions or other companies. As capital remains constrained and interest rates stay elevated, more businesses are turning to licensing as an alternative way to monetize valuable intellectual property rights and assets. Participants will gain insights into key considerations, market trends in life sciences licensing, and strategies for securing favorable terms. Plus, you’ll have the chance to eavesdrop on a mock negotiation.
Facilitating Market Access: Navigating the FDA and Reimbursement for Therapeutics, Devices, Diagnostics and Digital Health: Learn effective strategies to reduce regulatory barriers and streamline market access for medical products, focusing on the US Food and Drug Administration (FDA) requirements and US Centers for Medicare and Medicaid Service (CMS) and private payer reimbursement processes.
Enforcement and Compliance: Exploring the Latest Trends Impacting the Life Sciences Industry: Recent court activity – including at the Supreme Court – has significant implications for life sciences companies, both in the context of Government oversight and in terms of day-to-day compliance. From the rejection of “Chevron deference,” to litigation about the scope of the Anti-Kickback Statute, we will explore the practical impact of these and other developments.
